MASTER-2 Trial

The MASTER-2 trial pioneers the use of measurable residual disease (MRD) to modulate type and intensity of therapy for patients with newly diagnosed multiple myeloma. This trial studies deferral of transplantation for patients who achieve MRD negativity, the use of an anti-BCMA bispecific T-cell engager for patients MRD positive, and MRD-guided fixed duration therapy.